Porous bone scaffolds based on high-precision 3D printing technology gave recently been developed for use in bone defect repair. However, conventional scaffold materials have poor mechanical properties and low osteogenic activity, limiting their clinical use. In this study, a porous composite tissue-engineered bone scaffold was prepared using polylactic acid, nano-hydroxyapatite, and nano-magnesium oxide as raw materials for high-precision 3D printing. The composite scaffold takes full advantage of the personalized manufacturing features of 3D printers and can be used to repair complex bone defects in clinical settings. The composite scaffold combines the advantages of nano-hydroxyapatite, which improves the formability of scaffold printing, and of nano-magnesium oxide, which regulates pH during degradation and provide a good environment for cell growth. Additionally, nano-magnesium oxide and nano-hydroxyapatite have a bidirectional effect on promoting the compressive strength and osteogenic activity of the scaffolds. The prepared composite porous scaffolds based on 3D printing technology show promise for bone defect repair.
The growing prevalence of bisphosphonates (BPs) poses a formidable challenge to the treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ), for which effective therapeutic approaches remain scarce to date. This study introduces a chitosan-based thermosensitive composite hydrogel system (CS-bFGF) loaded with basic fibroblast growth factor (bFGF), which is engineered to accelerate the healing of tooth extraction sockets in rabbits following zoledronic acid administration. We conducted a comprehensive characterization of CS-bFGF, with a specific focus on its microstructure. In addition, in vitro assays demonstrated that the prepared CS-bFGF exhibited excellent cytocompatibility. The healing efficacy was evaluated at 3 months post-implantation of CS-bFGF into the tooth extraction sockets of zoledronic acid-treated rabbits. Gross examination and histological assessments revealed that the presence of CS-bFGF led to a significant reduction in total osteonecrosis and inflammatory infiltration in the BRONJ animal model, with a particularly marked improvement in the formation of new bone. These findings indicate that CS-bFGF holds substantial potential as a therapeutic agent for the management of BRONJ.
23 October 2026 in Journal of Stomatology Oral and Maxillofacial Surgery